393 related articles for article (PubMed ID: 15714984)
21. [Keyrole of endocrinology in the victory against prostate cancer].
Labrie F
Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
[TBL] [Abstract][Full Text] [Related]
22. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant hormone therapy: the Canadian trials.
Klotz L; Gleave M; Goldenberg SL
Mol Urol; 2000; 4(3):233-7;discussion 239. PubMed ID: 11062379
[TBL] [Abstract][Full Text] [Related]
24. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
Wilson KS; Ludgate CM; Wilson AG; Alexander AS
Can J Urol; 2000 Oct; 7(5):1099-103. PubMed ID: 11114872
[TBL] [Abstract][Full Text] [Related]
26. Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
Furukawa J; Miyake H; Takenaka A; Hara I; Fujisawa M
BJU Int; 2007 Aug; 100(2):310-4. PubMed ID: 17511772
[TBL] [Abstract][Full Text] [Related]
27. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
28. [Neoadjuvant androgen deprivation preceding to radical prostatectomy--its role in short-term and long-term outcomes].
Homma Y
Nihon Rinsho; 1998 Aug; 56(8):2162-6. PubMed ID: 9750527
[TBL] [Abstract][Full Text] [Related]
29. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
30. Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.
Beekman K; Morris M; Slovin S; Heller G; Wilton A; Bianco F; Scardino PT; Scher HI
Urology; 2005 May; 65(5):947-52. PubMed ID: 15882729
[TBL] [Abstract][Full Text] [Related]
31. [Neoadjuvant therapy of prostate carcinoma].
Ebert T
Praxis (Bern 1994); 1997 Nov; 86(46):1815-8. PubMed ID: 9454282
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
33. [Radical prostatectomy with neoadjuvant hormone therapy for cT3 prostate cancer].
Fujimoto H
Nihon Rinsho; 2005 Feb; 63(2):271-8. PubMed ID: 15714978
[TBL] [Abstract][Full Text] [Related]
34. [New development of endocrine therapy in prostate cancer].
Naito S
Gan To Kagaku Ryoho; 1996 May; 23(6):684-8. PubMed ID: 8645018
[TBL] [Abstract][Full Text] [Related]
35. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
37. [Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate].
Boccon-Gibod L
Prog Urol; 1997 Feb; 7(1):97-8. PubMed ID: 9116748
[No Abstract] [Full Text] [Related]
38. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
39. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
[TBL] [Abstract][Full Text] [Related]
40. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
